Dual Agonist⚖️ 20.9% Weight Loss📊 Free Tracker

Mounjaro/Zepbound Tracker App

Track Your Mounjaro/Zepbound Protocol

Mounjaro/Zepbound (Tirzepatide) is a gip+glp-1 dual agonist, FDA approved, used in SURMOUNT-1 with 20.9% weight loss at 72 weeks. Shotlee is the free app to track your complete Mounjaro/Zepbound protocol — doses, side effects, weight, and labs.

25,000+

Active Users

4.8★

App Rating

Free

Always Free

What Is Mounjaro/Zepbound?

Mounjaro/Zepbound (Tirzepatide) is a gip+glp-1 dual agonist, FDA approved, used in SURMOUNT-1 with 20.9% weight loss at 72 weeks. Shotlee is the free app to track your complete Mounjaro/Zepbound protocol — doses, side effects, weight, and labs.

Shotlee tracks every aspect of your Mounjaro/Zepbound protocol: injection dates, doses, sites, side effects, weight changes, and lab results. Whether you are starting or optimizing, clean data makes better decisions.

What to Track in Shotlee

Build a complete Mounjaro/Zepbound protocol record from day one.

💉

Dose Log

Record every injection date, dose amount, and administration route.

⚖️

Weekly Weight

Track body weight consistently to see your response curve over time.

🤢

Side Effects

Log any side effects with severity ratings to share with your prescriber.

🩸

Lab Results

Save blood work and biomarkers from clinic visits in one place.

📐

Measurements

Waist, hip, and other measurements reveal changes the scale may miss.

😴

Notes & Mood

Daily notes on energy, appetite, sleep, and overall wellbeing.

How to Track Your Mounjaro/Zepbound Protocol

01

Set a baseline: log your starting weight, measurements, and any available labs before your first dose

02

Record every dose: date, amount, injection site, and any immediate reactions

03

Log weekly weight at the same time and conditions to track your trend

04

Note side effects with severity so your prescriber can adjust your protocol

05

Add lab results from each clinic visit to measure biomarker improvements over time

Mounjaro/Zepbound Key Facts

Category

GIP+GLP-1 Dual Agonist

Tirzepatide (Mounjaro/Zepbound)

Status

FDA Approved

Approved 2022

Typical Dose

2.5-15 mg/week SC

2.5-15 mg/week SC

Protocol FAQs

Clinical trials show tirzepatide produces more weight loss (22% vs 15-17%) and better A1C reduction than semaglutide. However, individual results vary. Shotlee tracks both medications.

Sulfur burps (egg-smelling burps) are a unique side effect of tirzepatide not commonly seen with semaglutide. Shotlee helps you track this and identify triggers.

Yes! Many users get tirzepatide from telehealth providers. Shotlee supports custom dosing for compounded formulations.

Mounjaro is indicated for type 2 diabetes while Zepbound is for obesity. Your doctor can help decide. Shotlee tracks both identically.

Open the Shotlee app, navigate to the dose logging screen, select Tirzepatide as your medication, and enter the dose amount, injection site, and time. Shotlee stores all entries with timestamps and lets you view your complete dose history, adherence rate, and missed dose alerts. The app is free to download and use.

The most important side effects to track include gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), injection site reactions, appetite changes, energy levels, and any unusual symptoms. Log these daily in Shotlee so you can share accurate trend data with your healthcare provider at your next visit.

Most patients begin noticing appetite changes within the first one to two weeks. Measurable weight loss typically becomes apparent by weeks four to eight, depending on the dose titration schedule and individual metabolic response. Track your weekly weight in Shotlee to visualize your personal response curve over time.

References

  1. [1]Clinical TrialJastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(4):327-340.
  2. [2]Clinical TrialFrías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med. 2021;385(6):503-515.
  3. [3]FDAFDA. "Mounjaro (tirzepatide) injection, for subcutaneous use. Prescribing Information." NDA 215866. 2022.
  4. [4]FDAFDA. "Zepbound (tirzepatide) injection, for subcutaneous use. Prescribing Information." NDA 215959. 2023.

Track Your Mounjaro/Zepbound Protocol in Shotlee

Free dose logs, side effect tracking, weight trends, and lab results — all in one app.

🚀 Use Shotlee for Free